GlassScriptPhysician profile
James J Boehmke
NPI 1154309375
$14,189.50
in general payments reported to CMS, 2019-2025
42 companies · $2,421 in 2025
The $2,421 reported for 2025 was more than what 83% of Gastroenterology (Internal Medicine) providers received nationally (typical 2025 total: $636).
See the full distribution for Gastroenterology (Internal Medicine)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,615 · 2020: $1,320 · 2021: $2,261 · 2022: $2,156 · 2023: $2,095 · 2024: $2,322 · 2025: $2,421.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $6,784 · Education: $53.99.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $6,784.18 |
| Education | $53.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $3,852.57 | 2019-2025 | Rinvoq, Skyrizi, Linzess |
| Takeda Pharmaceuticals U.S.A., INC. | $2,115.35 | 2019-2025 | Entyvio, Eohilia, Gattex |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $1,286.66 | 2019-2025 | Trulance, Relistor, Xifaxan |
| Janssen Biotech, INC. | $1,139.29 | 2019-2025 | Stelara, Tremfya, Remicade |
| Pfizer INC. | $976.78 | 2019-2025 | |
| Gilead Sciences, INC. | $955.53 | 2019-2025 | |
| Ardelyx, INC. | $515.50 | 2022-2025 | Ibsrela |
| Genzyme Corporation | $473.54 | 2022-2025 | |
| Intercept Pharmaceuticals, INC. | $340.07 | 2019-2025 | Ocaliva |
| Lilly USA, LLC | $287.76 | 2024-2025 | Omvoh, Jardiance, Zepbound |
| Braintree Laboratories, INC. | $273.43 | 2020-2022 | |
| Evoke Pharma, INC. | $187.07 | 2021-2022 | |
| Merck Sharp & Dohme LLC | $178.56 | 2019-2024 | Dificid |
| Phathom Pharmaceuticals, INC. | $169.99 | 2024-2025 | Voquezna |
| Madrigal Pharmaceuticals | $163.80 | 2024-2025 | Rezdiffra, Resmetirom |
Show all 42 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw James Boehmke listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.